These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 31706700

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Antimalarials and amphotericin B interact synergistically and are new options to treat cryptococcosis.
    Freitas GJC, Ribeiro NQ, Gouveia-Eufrasio L, Emidio ECP, Guimarães GM, César IC, Paixão TA, Oliveira JBS, Caza M, Kronstad JW, Santos DA.
    Int J Antimicrob Agents; 2023 Jul; 62(1):106807. PubMed ID: 37030471
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Physiological Differences in Cryptococcus neoformans Strains In Vitro versus In Vivo and Their Effects on Antifungal Susceptibility.
    Grossman NT, Casadevall A.
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031206
    [Abstract] [Full Text] [Related]

  • 27. Terbinafine inhibits Cryptococcus neoformans growth and modulates fungal morphology.
    Guerra CR, Ishida K, Nucci M, Rozental S.
    Mem Inst Oswaldo Cruz; 2012 Aug; 107(5):582-90. PubMed ID: 22850947
    [Abstract] [Full Text] [Related]

  • 28. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.
    Andrade-Silva L, Ferreira-Paim K, Mora DJ, Da Silva PR, Andrade AA, Araujo NE, Pedrosa AL, Silva-Vergara ML.
    Med Mycol; 2013 Aug; 51(6):635-40. PubMed ID: 23343452
    [Abstract] [Full Text] [Related]

  • 29. A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs.
    Kim J, Cho YJ, Do E, Choi J, Hu G, Cadieux B, Chun J, Lee Y, Kronstad JW, Jung WH.
    Fungal Genet Biol; 2012 Nov; 49(11):955-66. PubMed ID: 22975303
    [Abstract] [Full Text] [Related]

  • 30. Combined in vitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans.
    Chen HH, Liushih RN, Hsieh WC.
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1982 May; 15(2):106-12. PubMed ID: 7047097
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.
    Mesa-Arango AC, Trevijano-Contador N, Román E, Sánchez-Fresneda R, Casas C, Herrero E, Argüelles JC, Pla J, Cuenca-Estrella M, Zaragoza O.
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6627-38. PubMed ID: 25155595
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
    Lee GA, Arthur I, Merritt A, Leung M.
    Med Mycol; 2019 Nov 01; 57(8):1004-1010. PubMed ID: 30649538
    [Abstract] [Full Text] [Related]

  • 37. Rimonabant potentiates the antifungal activity of amphotericin B by increasing cellular oxidative stress and cell membrane permeability.
    Zhang M, Lu J, Duan X, Chen J, Jin X, Lin Z, Pang Y, Wang X, Lou H, Chang W.
    FEMS Yeast Res; 2021 Apr 07; 21(3):. PubMed ID: 33705544
    [Abstract] [Full Text] [Related]

  • 38. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
    Rodero L, Córdoba S, Cahn P, Hochenfellner F, Davel G, Canteros C, Kaufman S, Guelfand L.
    J Antimicrob Chemother; 2000 Feb 07; 45(2):239-42. PubMed ID: 10660509
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.